James P Stevenson
Overview
Explore the profile of James P Stevenson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
1847
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roof L, Wei W, Tullio K, Pennell N, Stevenson J
JTO Clin Res Rep
. 2022 Jul;
3(7):100360.
PMID: 35815321
Objectives: To determine how the incidence and demographics of SCLC have changed over time and to evaluate whether patient demographics, disease presentation, and treatment characteristics affect patient outcomes. Methods: We...
2.
Sadaps M, Funchain P, Mahdi H, Grivas P, Pritchard A, Klek S, et al.
JCO Precis Oncol
. 2022 Feb;
2:1-11.
PMID: 35135160
Purpose: Precision oncology is widely discussed, but cohort studies are limited. We previously reported our prospective experience of precision oncology in solid tumors, and here we report our longitudinal experience,...
3.
Awad M, Gadgeel S, Borghaei H, Patnaik A, Yang J, Powell S, et al.
J Thorac Oncol
. 2020 Oct;
16(1):162-168.
PMID: 33069888
Introduction: In cohort G of KEYNOTE-021 (NCT02039674), first-line pembrolizumab plus pemetrexed-carboplatin significantly improved the objective response rate and progression-free survival versus chemotherapy alone with manageable toxicity in advanced nonsquamous NSCLC....
4.
Weiss J, Pennell N, Deal A, Morgensztern D, Bradford D, Crane J, et al.
Cancer
. 2020 Jan;
126(5):1060-1067.
PMID: 31943168
Background: The selection of later-line treatment for older patients with AJCC (version 7) stage IV non-small cell lung cancer (NSCLC) remains controversial. Nanoparticle albumin-bound (nab)-paclitaxel is approved with carboplatin for...
5.
Rengan R, Mick R, Pryma D, Lin L, Christodouleas J, Plastaras J, et al.
JAMA Oncol
. 2019 Aug;
5(10):1464-1472.
PMID: 31436839
Importance: Local failure after chemoradiotherapy (CT-RT) significantly contributes to mortality in patients with locally advanced non-small cell lung cancer (LA-NSCLC). One approach to improve local control is through targeted radiosensitization...
6.
Gubens M, Sequist L, Stevenson J, Powell S, Villaruz L, Gadgeel S, et al.
Lung Cancer
. 2019 Mar;
130:59-66.
PMID: 30885353
Objectives: Combination immunotherapy may result in improved antitumor activity compared with single-agent treatment. We report results from dose-finding and dose-expansion cohorts of the phase 1/2 KEYNOTE-021 study that evaluated combination...
7.
Gadgeel S, Stevenson J, Langer C, Gandhi L, Borghaei H, Patnaik A, et al.
Lung Cancer
. 2018 Nov;
125:273-281.
PMID: 30429032
Objectives: Platinum-based chemotherapy for advanced non-small-cell lung cancer (NSCLC) has modest benefit overall, but has the potential to amplify immune responses. In cohorts A-C of the multicohort phase 1/2 study...
8.
Khunger M, Patil P, Khunger A, Li M, Hu B, Rakshit S, et al.
PLoS One
. 2018 Oct;
13(10):e0197743.
PMID: 30359383
Background: The absolute neutrophil count (ANC), absolute lymphocyte count (ALC), absolute monocyte count (AMC) and neutrophil to lymphocyte ratio (NLR) are known markers of inflammation. We evaluated whether ANC, ALC,...
9.
Borghaei H, Langer C, Gadgeel S, Papadimitrakopoulou V, Patnaik A, Powell S, et al.
J Thorac Oncol
. 2018 Aug;
14(1):124-129.
PMID: 30138764
Introduction: Cohort G of KEYNOTE-021 (NCT02039674) evaluated the efficacy and safety of pembrolizumab plus pemetrexed-carboplatin (PC) versus PC alone as first-line therapy for advanced nonsquamous NSCLC. At the primary analysis...
10.
Wee C, Goodman L, Varella L, Rybicki L, Montero A, Estfan B, et al.
J Oncol Pract
. 2017 Jun;
13(7):e666-e672.
PMID: 28636421
Purpose: Hospital transfers may affect clinical outcomes. Evaluation of admission by source of transfer, time of admission, and provider type may identify opportunities to improve inpatient outcomes. Methods: We reviewed...